Patients with IBD treated with the original adalimumab reference product show a high acceptance of the switch to its ...

The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics may also be considered.

An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

The results of an open-label extension study confirmed the interchangeability of biosimilar CT-917 with reference adalimumab for plaque psoriasis.

Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, ...

Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort ...

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Both Generics and Biosimilars segments underperformed, though the latter was notably weaker, missing consensus by 9%.

Non-infectious uveitis is a rare immune-mediated condition in children and is often treated with the tumor necrosis factor inhibitor adalimumab. Discontinuing the drug may be considered when ...